

Charity registration number 1032256 (England and Wales)

**THE ASSOCIATION OF CANCER PHYSICIANS
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

THE ASSOCIATION OF CANCER PHYSICIANS

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Dr A Jones Professor R Begent
Secretary	Prof. S Ahmed
Charity number	1032256
Principal address	c/o Mrs A Norton Department of Medicine Royal Marsden Hospital Downs Road, Sutton Surrey SM2 5PT
Independent examiner	Rouse Partners LLP 55 Station Road Beaconsfield Buckinghamshire United Kingdom HP9 1QL
Bankers	National Westminster Bank Plc

THE ASSOCIATION OF CANCER PHYSICIANS

CONTENTS

	Page
Trustees report	1 - 4
Independent examiner's report	5
Statement of financial activities	6
Balance sheet	7
Notes to the accounts	8 - 15

THE ASSOCIATION OF CANCER PHYSICIANS

TRUSTEES REPORT

FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees present their annual report and financial statements for the year ended 31 December 2024.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the constitution's governing document, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)"

Objectives and activities

The objectives of the Association of Cancer Physicians (ACP) are to advance the study and practice of cancer medicine (medical oncology), to represent the interests of medical oncologists and to foster the raising of standards in medical care for cancer patients. It is also the aim to facilitate contact between members of the Association and other individuals and organisations concerned with the study and treatment of cancer and with the public at large.

Applications for membership are approved by the Executive Committee and ratified at the AGM. Members and officers of the Executive Committee are nominated by the membership in line with the Constitution and Rules (updated 2013) and a vote of eligible members is organised in the event of a surplus of nominations for the vacant positions. The Chair is appointed for a period of three years that may be extended for a second term of office. The Executive Committee includes Officers supported by regional representatives from across the UK, together with other designated roles and ex officio members. There are also up to three trainee representatives and one representative of the New Consultants Group on the Executive Committee. Professor Andrew Wardley was appointed as Chair of the ACP in April 2023 and Dr Graham Dark is Deputy Chair. Professor Samreen Ahmed is the Secretary, Professor Helena Earl is the Honorary President, and Dr Tania Tillett is Treasurer.

Public benefit

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the constitution should undertake.

Achievements and performance

Significant activities and achievements against objectives

During 2024, the Association of Cancer Physicians continued to support a wide range of activities to advance the study and practice of cancer medicine and to help raise standards of medical care for patients.

The ACP AGM was held remotely by Zoom in November 2024, with good attendance. The Executive Committee has found that a virtual AGM helps to facilitate better participation and interaction with the membership from across the UK, in addition to reducing travel for members and reducing costs for all. The meeting is also recorded for members unable to join the live event. At the AGM there was a vote on a proposal for the ACP to change its name to better reflect the role of medical oncologists in the NHS and globally, and to align with the naming conventions of ESMO and other European oncology societies. The proposed new name, the UK Society for Medical Oncology (UKSMO) was agreed by a majority vote at the AGM (in addition to a majority vote of those unable to attend the AGM). The process of transitioning of name from ACP to UKSMO is now underway.

Involvement in and support for medical oncology training, including teaching and education, remains a high priority for the ACP and in 2024 continued to hold both online and face to face educational events.

The ACP recognises that entry from trainee into consultant grade can be a challenging time for members as they learn to take on leadership and management responsibilities while taking charge of their clinical workload. To help medical oncologists through this difficult time the ACP has established an annual New Consultants Group (NCG) meeting. Providing peer support through networking opportunities, together with targeted lectures, the meeting is aimed at all medical oncology consultants within 5 years of their first substantive consultant appointment in addition to trainees in the final year of their training. These very popular meetings have now been run for over 20 years and receive excellent feedback, both from delegates, speakers and also sponsors. With the generous support of pharmaceutical sponsorship, the ACP keeps these meetings free of charge for members to attend. The 2024 meeting was held at the Crowne Plaza Hotel in central Birmingham in March and included a balance of clinical updates from experts and non-clinical sessions, to support the professional and personal development of attendees, including people management and leadership skills.

THE ASSOCIATION OF CANCER PHYSICIANS

TRUSTEES REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

As further acknowledgement of the additional support that can help bridge the transition from training to taking up a consultant post, the ACP is establishing a mentorship scheme, by providing a platform for connecting mentees with potential mentors. This is currently being set up with a view to launching in early 2025. Specialist trainees and early-career consultants will both be eligible to register for the scheme, as well as non-training grades/SAS doctors who are aiming to apply for specialist accreditation via the portfolio pathway route.

The ACP was delighted to hold an annual meeting for specialty trainees in medical oncology in Leeds in November 2024. This meeting had the theme of "Precision Oncology". Cancer treatment is becoming increasingly tailored to the individual patient, with an ever increasing number of targeted therapies. The programme therefore explored the role of molecularly targeted therapies and individually tailored treatments in a variety of tumour sites. In addition, attendees heard from experts in the field about the future of Precision Oncology and personalised treatment in the form of cancer vaccines, ctDNA guided therapy, whole genome sequencing and cellular therapies. Feedback from attendees was that this was a very interesting and educational meeting. Although the meeting was generously supported by pharmaceutical sponsors, the costs of running these events is considerable, so, for the first time for an ACP trainee meeting, trainees were asked to make a small contribution towards their attendance costs. However, overwhelming feedback was that this small cost still represented good value for money for a valuable educational and networking experience, and is still below that charged for similar events by other organisations.

The ACP works closely with the SAC (Specialty Advisory Committee) for Medical Oncology, which looks after training, education and recruitment in medical oncology, at the RCP (Royal College of Physicians). Trainees in medical oncology have to take and pass an exam (Specialist Certificate Exam – SCE), to demonstrate that they have sufficient knowledge to practise safely and competently as consultants. To provide trainees with additional support with studying for the exam, the ACP has published an evidence-based resource to aid revision and support further learning "500 SBAs for the Medical Oncology Specialty Certificate Exam" and, due to the fast pace in the development of new therapies in oncology, an updated edition is being prepared. The book contains questions and answers on the current investigations and management in UK cancer clinical practice. Trainees have found the book very useful to help with exam preparation. The ACP supported the costs of this publication and an agreement with the publishers, EBN Health, also allowed members to benefit from a discount on the purchase price.

The ACP continues to advocate for an expansion in the cancer workforce. Demand for systemic therapy has been increasing year on year, and this growth is expected to continue, due to the pressures of an aging population, an increased incidence of cancer, combined with welcome but rapid advances in genomics and new therapeutic options. The specialty welcomed a further significant increase in specialty training numbers in medical oncology allocated in 2024, however feels strongly that this expansion needs to be continued in future years to develop a workforce to deliver world leading cancer services in the future.

The ACP continues to support the SAC in the promotion of medical oncology as a future career for medical students and resident doctors, and has been closely involved in efforts to enhance the visibility and attractiveness of medical oncology careers. Two webinars have been held, one jointly with the Royal College of Radiologists (RCR), to promote oncology as a career. The ACP hosted a webinar in September 2024 which was very well attended, with plenty of opportunities for Q&A, and the recording was made publicly available on the ACP and RCP website to support recruitment into the specialty. The ACP also collaborates and promotes BONUS (British Oncology Network for Undergraduate Societies) and NOTCH (National Oncology Trainees Collaborative for Healthcare Research) with mentoring, support and speaker engagement.

There are widespread concerns about sustained workforce shortages in cancer services, due to increasing demand for treatment outstripping consultant expansion. Oncology departments across the UK continue to face capacity issues, which is impacting on SACT delivery. The ACP has been a co-signatory on letters to the Secretary of State for Health and Social Care, and the CMO for Scotland, highlighting challenges facing cancer services. The ACP is planning a comprehensive workforce census to capture the medical oncology/chemotherapy prescribing workforce, with the granularity that should be very helpful in future workforce planning.

The ACP continued their series of live monthly teaching webinars, originally started in 2020, to supplement local and regional teaching. Topics covered in 2024 included a wide range of both common and rarer cancers and these continue to attract sizeable audiences and excellent feedback. The recordings of all the webinars are edited and made available free of charge to all ACP members, to those unable to join the live event, or would like to view the recording again in their own time.

THE ASSOCIATION OF CANCER PHYSICIANS

TRUSTEES REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

The ACP continues to work closely with EBN Health, an experienced healthcare publishing company, to produce and support its publications. These have been very successful, with several of the publications awarded the BMA Oncology Prize. The ACP and EBN Health have also established a digital platform as an educational resource to benefit members. This allows access to the full searchable content of the ACP/EBN publications and also includes recordings from the teaching webinars.

The ACP has a reciprocal membership agreement with ESMO (European Society for Medical Oncology), and ESMO representatives sit on the ACP Executive Committee. The ACP collaborates closely with ESMO, and ACP members benefit from a reduced membership subscription to ESMO in addition to access to their extensive programme of activities to support career development.

As in previous years, excellence in research amongst trainees is encouraged by the award of two annual McElwain prizes, one for a clinical project and one for translational research, in addition to a President's Prize. The three prize-winners are invited to present their work to their peers at the annual ACP trainees' weekend in Leeds, in addition to receiving a financial reward.

The ACP continues to be closely involved with and is a parent body of the UK SACT (Systemic Anti-Cancer Treatment) Board (previously the UK Chemotherapy Board), which provides guidance, oversight and support for the continuing development of systemic therapy services across the UK. The UK SACT Board hosts an annual meeting focused on developing and supporting the delivery of SACT services, which is very well attended. The UK SACT Board has been key in the development and oversight of national standardised SACT regimen-specific and generic consent forms. The aim is to support clinicians throughout the UK in ensuring that all patients are fully informed when consenting to SACT. The UK SACT Board has also established workstreams to undertake audits and produces national guidance and patient-supporting materials to support improvements in the delivery of systemic therapy in the UK. The chairmanship of the UK SACT Board rotates annually among its parent bodies and in 2024 was chaired by Dr Roshan Agarwal, on behalf of the ACP.

The ACP is also a member of the Inequalities in Health Alliance, a multi-professional collaborative group launched by the RCP in 2020, to campaign for a cross-government strategy to address and reduce health inequalities.

Since 2019, Working Groups from the ACP, the Royal Colleges of Physicians and The Royal College of Radiologists (RCR) have been exploring the benefits - to patients, the NHS and to clinicians – of closer working between the two specialties of Clinical Oncology and Medical Oncology. The initial exploration of closer working and closer alignment in training in clinical oncology and medical oncology resulted in a common first year of training in both specialties, implemented in August 2021. Discussions and consultation with members and other stakeholders are continuing, with the shared goal of:

- Improving the quality and efficiency of cancer care and patient outcomes in many areas including Acute Oncology (AO).
- Strengthening both specialties by working together and providing a robust, flexible framework for future developments in cancer care.
- Having a stronger joint voice for the two specialties together, increasing their influence for the benefit of services and patients.

After wide ranging analysis and consultations, a Closer Working Group concluded that the best eventual solution would be for Clinical Oncology and Medical Oncology to remain as two separate specialties but to form a new Joint Faculty, hosted within the RCR. Despite this, following a detailed investigation of the current financial, operational and governance issues, it was clear that this was not currently possible. However, the Closer Working Group recommended that Clinical Oncology and Medical Oncology should establish a joint committee to develop plans for closer working in several areas, including policy and strategy, training and education, professional guidance and workforce development. They should work together towards the formation of a Joint Faculty when it became possible to do so, and a template for such a faculty has already been agreed.

A Joint Working Group (JWG) (formed of senior representatives from both the RCR Faculty of Clinical Oncology and the ACP) was therefore established in 2023, and held three meetings in 2024. The JWG has been exploring five main areas for potential joint working during its first year: workforce planning and development, including specialty recruitment; policy, including SACT workforce crisis, and consultant recruitment; training; professional guidance; education. A report outlining progress to date was published in late 2024.

The ACP contracts with SAS, an association management company, to provide support for the organisation of the ACP's programme of educational events, in addition to managing its membership activities and collection of subscriptions.

THE ASSOCIATION OF CANCER PHYSICIANS

TRUSTEES REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Financial review

Financially, the ACP's main source of income is from members subscriptions, with additional sponsorship and educational grants from the pharmaceutical industry to support educational activities. SAS is contracted to manage the ACP's educational meetings, in addition to maintaining the membership database and responsibility for the collection of subscription income. It is hoped that this will maximise subscription income going forward. The current account runs in credit. Travel costs incurred by Executive members and secretarial costs have previously been the main expenditures, although travel continued to be severely restricted in 2024, with a move to meetings being held virtually. Further substantial expenditure was on educational events and publishing activities supported by receipt of restricted and unrestricted Educational Grants and sponsorships.

Reserves policy

Reserves Policy

The association ensures there is sufficient money to meet its annual commitments. A separate fund entitled the McElwain Fund also exists for the presentation of prizes and scholarships in respect of studies to advance the objectives of the association.

At the year end unrestricted reserves were £14,441 (2023: £41,262) and restricted reserves were negative £19,661 (2023: £22,202).

Major risks

The trustees have assessed the major risks to which the constitution is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

Structure, governance and management

The Association of Cancer Physicians was set up in 1985 and then formally adopted the constitution on 29 March 1993 and was registered by the charity commission on 28 January 1994 (charity number 1032256).

The trustees who served during the year were:

Dr A Jones

Professor R Begent

Recruitment and appointment of trustees

New trustees are appointed by the Executive Committee and 2-3 nominations were made this year who are being approached about serving in this capacity. Particular emphasis is placed upon the appointment of trustees with knowledge and experience relevant to the charity's charitable activities as well as other trustees with the specialty to offer complementary skills eg accounting and marketing.

Public Benefit Statement

Guidance from the Charity Commission has been used to review and develop The Association of Cancer Physicians aims and objectives so that activities are clearly focused to derive good public benefit.

The trustees report was approved by the Board of Trustees.

.....
Dr A Jones

Date:

THE ASSOCIATION OF CANCER PHYSICIANS

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF THE ASSOCIATION OF CANCER PHYSICIANS

I report to the trustees on my examination of the financial statements of The Association of Cancer Physicians (the constitution) for the year ended 31 December 2024.

Responsibilities and basis of report

As the trustees of the constitution you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011.

I report in respect of my examination of the constitution's financial statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the Charities Act 2011.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the constitution as required by section 130 of the Charities Act 2011.
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of financial statements set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the financial statements give a true and fair view, which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Rouse Partners LLP

55 Station Road
Beaconsfield
Buckinghamshire
HP9 1QL
United Kingdom

Date:

THE ASSOCIATION OF CANCER PHYSICIANS

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

		Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
	Notes						
Income and endowments from:							
Donations and legacies	2	32,844	66,875	99,719	49,129	31,965	81,094
Investments	3	-	2	2	-	23	23
Other income	4	1,034	-	1,034	849	-	849
Total income		33,878	66,877	100,755	49,978	31,988	81,966
Expenditure on:							
Charitable activities	5	35,044	95,073	130,117	35,407	94,901	130,308
Total expenditure		35,044	95,073	130,117	35,407	94,901	130,308
Net expenditure		(1,166)	(28,196)	(29,362)	14,571	(62,913)	(48,342)
Transfers between funds		(25,655)	25,655	-	(40,000)	40,000	-
Net movement in funds		(26,821)	(2,541)	(29,362)	(25,429)	(22,913)	(48,342)
Reconciliation of funds:							
Fund balances at 1 January 2024		41,262	22,202	63,464	66,691	45,115	111,806
Fund balances at 31 December 2024		14,441	19,661	34,102	41,262	22,202	63,464

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

THE ASSOCIATION OF CANCER PHYSICIANS

BALANCE SHEET

AS AT 31 DECEMBER 2024

	Notes	2024 £	£	2023 £	£
Current assets					
Debtors	10	14,830		40,276	
Cash at bank and in hand		24,150		30,484	
		<u>38,980</u>		<u>70,760</u>	
Creditors: amounts falling due within one year	11	(4,878)		(7,296)	
Net current assets			<u>34,102</u>		<u>63,464</u>
The funds of the constitution					
Restricted income funds	12		19,661		22,202
Unrestricted funds	13		14,441		41,262
			<u>34,102</u>		<u>63,464</u>

The financial statements were approved by the trustees on

.....
Dr A Jones

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

Company information

The Association of Cancer Physicians is an unincorporated association, constituted under a Governing Document dated 29 March 1993 and is a registered charity in the United Kingdom reference 1032256. The address of the registered office is given on the legal and administrative information page of these financial statements.

1.1 Accounting convention

These accounts have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), "Accounting and Reporting by Charities" the Statement of Recommended Practice for charities applying FRS 102, the Charities Act 2011 and UK Generally Accepted Accounting Practice as it applies from 1 January 2015. The constitution has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows. The constitution is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the constitution. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the constitution has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Incoming resources

Income is recognised when the constitution is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

All incoming resources are included in the Statement of Financial Activities (SOFA) when receivable.

Grants receivable are recognised when all performance conditions are satisfied and they have been received.

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

1.5 Resources expended

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under the following headings:

Expenditure on charitable activities includes support and governance costs which are incurred in running the charity.

Support costs are those that assist the work of the charity and include office costs, governance costs and administrative costs. They are incurred directly in support of expenditure on the objects of the charity and allocated to expenditure on charitable activities on a basis consistent with use of the resources.

All expenditure is accounted for on an accruals basis and includes irrecoverable VAT. Direct costs are allocated to the particular activity.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The constitution has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the constitution's balance sheet when the constitution becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are measured at transaction price.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are recognised at transaction.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities.

Derecognition of financial liabilities

Financial liabilities are derecognised when the constitution's contractual obligations expire or are discharged or cancelled.

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

2 Donations and legacies

	Unrestricted funds	Restricted funds	Total 2024	Total 2023
	£	£	£	£
Grants	8,573	66,875	75,448	43,994
Membership fees & sponsorships	24,271	-	24,271	37,100
	<u>32,844</u>	<u>66,875</u>	<u>99,719</u>	<u>81,094</u>
For the year ended 31 December 2023	<u>49,129</u>	<u>31,965</u>		<u>81,094</u>

3 Income from investments

	Restricted funds 2024	Restricted funds 2023
	£	£
Interest receivable	<u>2</u>	<u>23</u>

4 Other income

	Unrestricted funds 2024	Unrestricted funds 2023
	£	£
Royalties	<u>1,034</u>	<u>849</u>

5 Charitable activities

	2024	2023
	£	£
Prizes	3,000	3,500
Meeting and Travel Expenses	96,321	83,958
Publishing Services	1,784	12,500
	<u>101,105</u>	<u>99,958</u>
Share of governance costs	29,012	30,350
	<u>130,117</u>	<u>130,308</u>

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

6 Support costs

	Support costs £	Governance costs £	2024 £	2023 £	Basis of allocation
Secretarial Services	-	14,607	14,607	15,459	Governance
Independent examination	-	2,775	2,775	3,150	Governance
Sundry expenses	-	858	858	-	Governance
Bank charges	-	57	57	70	Governance
	<u>-</u>	<u>18,297</u>	<u>18,297</u>	<u>18,679</u>	
Analysed between Charitable activities	<u>-</u>	<u>29,012</u>	<u>29,012</u>	<u>30,350</u>	

7 Trustees

None of the trustees (or any persons connected with them) received any remuneration during the year.

8 Employees

The average monthly number of employees during the year was:

	2024 Number	2023 Number
Total	<u>-</u>	<u>-</u>

There were no employees whose annual remuneration was more than £60,000.

9 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

10 Debtors

	2024 £	2023 £
Amounts falling due within one year:		
Trade debtors	5,000	9,000
Other debtors	5,716	28,705
Prepayments and accrued income	4,114	2,571
	<u>14,830</u>	<u>40,276</u>

11 Creditors: amounts falling due within one year

	2024 £	2023 £
Accruals and deferred income	<u>4,878</u>	<u>7,296</u>

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

12 Restricted funds

The restricted fund in relation to the McElwain fund is a separate fund that exists for the award of prizes and scholarships in respect of educational and research studies to advance the objects of the association.

The New Consultants Weekend fund was set up to specifically support senior trainees and consultants in the first 5 years of their appointments. An annual event is held to allow discussions both amongst themselves and with invited more senior mentors about topics facing them at this point in their career.

The Bagshawe Lecture Fund was established following a donation by the trustees of the Post Natal Chorionepithelioma Trust (PNCT) when the charity was dissolved in 2018. The funds support an annual named “Bagshawe” lecture. In 2024 the lecture was given by Professor Carlos Caldas, from the University of Cambridge, whose talk “Whole Genome Sequencing in Oncology: Current landscape and future directions” was a highlight of the Precision Oncology meeting in Leeds in November.

The Acute Oncology Workshop Fund was set up to support a one-day meeting in Leeds, “Acute Oncology: Challenges and Opportunities”, a joint collaboration with the UK Acute Oncology Society, followed by the annual trainees weekend, which also had an acute oncology focus. This meeting brought together a panel of multidisciplinary speakers to address some of the dilemmas faced by everyone working in Acute Oncology. There was a focus on how acute oncology fits into the medical oncology curriculum and the current NHS landscape, and how best to support the continued development of acute oncology services across the UK.

The ACP Problem Solving in Oncology Webinar fund was set up to support a series of monthly teaching webinars which were launched in October 2020. Sponsored by pharmaceutical companies and hosted on Zoom, the live webinars were initially started to provide additional teaching to compensate for the reduction in local, regional and national educational opportunities during the COVID-19 pandemic. Due to their popularity, the live webinars continue on a monthly basis and are recorded, with the recordings available free of charge to ACP members.

The Precision Oncology Meeting fund was set up to support a two-day meeting in Leeds, “Precision Oncology”. The meeting brought together specialist trainees in medical oncology from across the UK, to learn how cancer treatment is becoming increasingly tailored to the individual patient, with an ever increasing number of targeted therapies. The programme explored the role of molecularly targeted therapies and individually tailored treatments in a variety of tumour sites. In addition, attendees heard from expert speakers about the future of precision oncology and personalised treatment, in the form of cancer vaccines, ctDNA guided therapy, whole genome sequencing and cellular therapies.

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

12 Restricted funds

(Continued)

	Movement in funds				Movement in funds				Balance at 31 December 2024
	Balance at 1 January 2023	Incoming resources	Resources expended	Transfer from unrestricted funds	Balance at January 2024	Incoming resources	Resources expended	Transfer from unrestricted funds	
	£	£	£	£	£	£	£	£	£
McElwain	1,998	23	(3,000)	-	(979)	2	(3,000)	-	(3,977)
New Consultants Weekend	11,915	14,500	(17,948)	-	8,467	16,075	(22,624)	-	1,918
Bagshawe Lecture	29,012	-	(7,500)	-	21,512	-	-	-	21,512
BSIR Interventional Oncology Study Day and Publication	12,192	-	-	-	12,192	-	(12,192)	-	-
Oncology Webinar Series	(6,192)	2,500	(4,414)	-	(8,106)	-	(3,919)	-	(12,025)
Advances in Biotherapies Workshop	(3,810)	-	-	-	(3,810)	-	-	3,810	-
Acute Oncology Workshop	-	13,905	(60,090)	40,000	(6,185)	(2,400)	(12,371)	20,956	-
ACP Dinner	-	1,060	(1,949)	-	(889)	-	-	889	-
Precision Oncology Workshop	-	-	-	-	-	53,200	(40,967)	-	12,233
	<u>45,115</u>	<u>31,988</u>	<u>(94,901)</u>	<u>40,000</u>	<u>22,202</u>	<u>66,877</u>	<u>(95,073)</u>	<u>25,655</u>	<u>19,661</u>

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

13 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 January 2024	Incoming resources	Resources expended	Transfers	At 31 December 2024
	£	£	£	£	£
General funds	41,262	33,878	(35,044)	(25,655)	14,441
	<u>41,262</u>	<u>33,878</u>	<u>(35,044)</u>	<u>(25,655)</u>	<u>14,441</u>
Previous year:	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
General funds	66,691	49,978	(35,407)	(40,000)	41,262
	<u>66,691</u>	<u>49,978</u>	<u>(35,407)</u>	<u>(40,000)</u>	<u>41,262</u>

14 Analysis of net assets between funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
At 31 December 2024:			
Current assets/(liabilities)	14,441	19,661	34,102
	<u>14,441</u>	<u>19,661</u>	<u>34,102</u>
	<u>14,441</u>	<u>19,661</u>	<u>34,102</u>
	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
At 31 December 2023:			
Current assets/(liabilities)	41,262	22,202	63,464
	<u>41,262</u>	<u>22,202</u>	<u>63,464</u>
	<u>41,262</u>	<u>22,202</u>	<u>63,464</u>

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

15 Related party transactions

There were no disclosable related party transactions during the year.